Cellular Biomedicine Group to Present Cancer CAR-T CD30 Therapy Clinical Development Program

Cellular Biomedicine Group Inc.

("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that management will present the Company's Chimeric Antigen Receptor T cell (CAR-T) therapy for cancer clinical development programs at the previously announced 10th Annual World Stem Cells & Regenerative Medicine Congress to be held at the Business Design Centre in London, UK on May 20-22, 2015. Dr. William (Wei) Cao, Chief Executive Officer, will speak on May 21, 2015 at 2:50pm during the segment titled "Spotlight On T-Cells". He will present Phase I clinical data from the Company's CAR-T programs, specifically the recombinant expression vector CD30 for Hodgkin's lymphoma. More information about the Congress and registration information can be found here.